Company Description
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies.
In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.
Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services.
The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
| Country | United States |
| Founded | 1904 |
| IPO Date | May 17, 2019 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 7,570 |
| CEO | Michael Stubblefield |
Contact Details
Address: Radnor Corporate Center, Building One Radnor, Pennsylvania 19087 United States | |
| Phone | 610 386 1700 |
| Website | avantorsciences.com |
Stock Details
| Ticker Symbol | AVTR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001722482 |
| CUSIP Number | 05352A100 |
| ISIN Number | US05352A1007 |
| Employer ID | 82-2758923 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Michael Stubblefield | Chief Executive Officer |
| R. Jones | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 8, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 10-Q | Quarterly Report |
| Oct 25, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 144 | Filing |
| Aug 26, 2024 | 144 | Filing |
| Aug 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 31, 2024 | 144 | Filing |